Bergen, Norway

BerGenBio is a clinical-stage, biopharmaceutical company based in Bergen, Norway and Oxford, UK. It is developing innovative therapies for aggressive cancers by way of inhibiting the AXL signalling pathway. The lead oncology compound, bemcentinib, is in multiple Phase II trials.

Investment Perspective

BerGenBio has raised NOK74.2m in a private placement to advance its clinical pipeline, as it plans the late stage Phase II studies in acute myeloid leukaemia (AML) and non-small cell lung cancer (NSCLC) with bemcentinib. Promising efficacy signals have been seen during the current Phase II study in AML as a monotherapy, and the latest data continues to suggest that bemcentinib enhances the activity of LDAC chemotherapy. Similarly, the current Phase II trial in NSCLC with bemcentinib in combination with pembrolizumab (Merck’s Keytruda) suggests the two therapies act synergistically. Following the capital raise, we value BerGenBio at NOK3.21bn (NOK53.13/share).

Market information

SymbolPrimary exchanges


Private placement to support randomised Phase II trials
Update | 19 Jun 2019
ASCO: more supportive data for bemcentinib
Update | 05 Jun 2019
Efficacy endpoint met in Phase II AML study
Lighthouse | 02 Apr 2019

Recent News

Preliminary Phase II AML data for bemcentinib in combination with low dose chemotherapy at EHA 2019
14 Jun 2019
Completed private placement
14 Jun 2019
Phase II elderly AML data for bemcentinib in combination with low dose chemotherapy at ASCO 2019
03 Jun 2019
Preliminary clinical and biomarker data from Phase II advanced NSCLC trial with bemcentinib and Keytruda at ASCO 2019
02 Jun 2019